Evidence map›Paper›PMID 32850757›Full record

ArticleFrontiers in bioengineering and biotechnology2020

Second-Generation RT-QuIC Assay for the Diagnosis of Creutzfeldt-Jakob Disease Patients in Brazil.

Breno José Alencar Pires Barbosa, Bruno Batitucci Castrillo, Ricardo Pires Alvim, Marcelo Houat de Brito, Helio R Gomes, Sônia M D Brucki, Jerusa Smid, Ricardo Nitrini, Michele C Landemberger, Vilma R Martins and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Breno José Alencar Pires BarbosaDepartment of Neurology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.
Bruno Batitucci CastrilloDepartment of Neurology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.
Ricardo Pires AlvimDepartment of Neurology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.
Marcelo Houat de BritoDepartment of Neurology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.
Helio R GomesDepartment of Neurology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.
Sônia M D BruckiDepartment of Neurology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.
Jerusa SmidDepartment of Neurology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.
Ricardo NitriniDepartment of Neurology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.
Michele C LandembergerTumor Biology and Biomarkers Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.
Vilma R MartinsTumor Biology and Biomarkers Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.
Jerson L SilvaNational Center of Nuclear Magnetic Resonance Jiri Jonas, Institute of Medical Biochemistry Leopoldo de Meis, National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro-UFRJ, Rio de Janeiro, Brazil.
Tuane C R G VieiraNational Center of Nuclear Magnetic Resonance Jiri Jonas, Institute of Medical Biochemistry Leopoldo de Meis, National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro-UFRJ, Rio de Janeiro, Brazil.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRAC Camargo Hospital · BRUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent development of IQ-CSF, the second generation of real-time quaking-induced conversion (RT-QuIC) using cerebrospinal fluid (CSF), for the diagnosis of Creutzfeldt-Jakob Disease (CJD) represents a major diagnostic advance in the field. Highly accurate results have been reported with encouraging reproducibility among different centers. However, availability is still insufficient, and only a few research centers have access to the method in developing countries. In Brazil, we have had 603 suspected cases of CJD since 2005, when surveillance started. Of these, 404 were undiagnosed. This lack of diagnosis is due, among other factors, to the lack of a reference center for the diagnosis of these diseases in Brazil, resulting in some of these samples being sent abroad for analysis. The aim of this research study is to report the pilot use of IQ-CSF in a small cohort of Brazilian patients with possible or probable CJD, implementing a reference center in the country. We stored CSF samples from patients with possible, probable or genetic CJD (one case) during the time frame of December 2016 through June 2018. All CSF samples were processed according to standardized protocols without access to the clinical data. Eight patients presented to our team with rapidly progressive dementia and typical neurological signs of CJD. We used CSF samples from seven patients with other neurological conditions as negative controls. Five out of seven suspected cases had positive tests; two cases showed inconclusive results. Among controls, there was one false-positive (a CSF sample from a 5-year-old child with leukemia under treatment). The occurrence of a false positive in one of the negative control samples raises the possibility of the presence of interfering components in the CSF sample from patients with non-neurodegenerative pathologies. Our pilot results illustrate the feasibility of having CJD CSF samples tested in Brazilian centers and highlight the importance of interinstitutional collaboration to pursue a higher diagnostic accuracy in CJD in Brazil and Latin America.

Indexed as

biomarkersCreutzfeldt-Jakob diseaseprionrapidly progressive dementiareal-time quaking-induced conversion

Identifiers

PMID32850757
PMCPMC7423993
OpenAlexW3047845691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.